Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
复制标题
DOI：
10.1182/blood-2017-03-769620
复制
发表时间：
2017-10-19
期刊：
影响因子：
20.3
通讯作者：
Gisselbrecht, Christian
中科院分区：
文献类型：
--
作者：
Crump, Michael;Neelapu, Sattva S.;Gisselbrecht, Christian
弥漫性大 B 细胞淋巴瘤 (DLBCL) 是非霍奇金淋巴瘤最常见的亚型。尽管一线治疗的 5 年生存率为 60% 至 70%，但高达 50% 的患者在治疗后变得难治或复发。已发表的对难治性 DLBCL 患者的大规模结果数据的分析有限。 SCHOLAR-1 是一项国际多队列回顾性非霍奇金淋巴瘤研究，回顾性评估了难治性 DLBCL 患者的结局，在本研究中，将其定义为疾病进展或疾病稳定，即化疗期间任何时间点的最佳反应（> 4 个周期的一线治疗或 2 个周期的后期治疗）或复发
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractory DLBCL are limited. SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (> 4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at